Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taliglucerase alfa
- Development stage
- Approved
- Lead developer
- Protalix
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Taliglucerase alfa is a recombinant form of the human lysosomal enzyme β-glucocerebrosidase, produced using a plant cell expression system. It is used as an enzyme replacement therapy for patients with Type 1 Gaucher disease, a genetic disorder characterized by deficiency of glucocerebrosidase leading to accumulation of glucocerebroside in various tissues. Taliglucerase alfa catalyzes the hydrolysis of glucocerebroside into glucose and ceramide, thereby reducing pathological lipid accumulation and improving symptoms such as hepatosplenomegaly, anemia, thrombocytopenia, and bone disease. The drug was developed using ProCellEx technology by Protalix BioTherapeutics and is marketed under the brand name Elelyso[2][3][4][6].
- Brand names
- Elelyso
- Other names
- glucosylcerebrosidase
02
Targets
Sphingolipid (Sphingolipid metabolism)
Beyond the preview
Go deeper on taliglucerase alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taliglucerase alfa.